Naloxone infusion — Competitive Intelligence Brief

Naloxone infusion (Naloxone infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid antagonist. Area: Emergency Medicine / Toxicology.

marketed Opioid antagonist Opioid receptors (mu, delta, kappa) Emergency Medicine / Toxicology Small molecule

Target snapshot

Naloxone infusion (Naloxone infusion) — Middle Tennessee Research Institute. Naloxone is an opioid antagonist that blocks opioid receptors to reverse opioid overdose and respiratory depression.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Naloxone infusion TARGET	Naloxone infusion	Middle Tennessee Research Institute	marketed	Opioid antagonist	Opioid receptors (mu, delta, kappa)
Symproic	NALDEMEDINE	Bdsi	marketed	Opioid Antagonist	Mu-type opioid receptor	2017-01-01
Movantik	NALOXEGOL	Averitas	marketed	Opioid Antagonist	Mu-type opioid receptor	2014-01-01
Entereg	ALVIMOPAN	Cubist Pharms	marketed	Opioid Antagonist	µ-opioid receptor	2008-01-01
Relistor	METHYLNALTREXONE	Salix Pharms	marketed	Opioid Antagonist	Mu-type opioid receptor	2008-01-01
Revex	NALMEFENE	Hikma	marketed	Opioid Antagonist	Kappa-type opioid receptor	1995-01-01
Narcan	NALOXONE	Adapt	marketed	Opioid Antagonist	Mu-type opioid receptor	1971-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid antagonist class)

1. Norwegian University of Science and Technology · 2 drugs in this class
2. Green Cross Corporation · 1 drug in this class
3. Middle Tennessee Research Institute · 1 drug in this class
4. Develco Pharma Schweiz AG · 1 drug in this class
5. Pacific Institute for Research and Evaluation · 1 drug in this class
6. Pfizer · 1 drug in this class
7. NYU Langone Health · 1 drug in this class